PRISCOLINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRISCOLINE is an injectable small molecule product approved in 1948 by Novartis with an unknown mechanism of action and indication profile. The drug's historical approval and current lifecycle stage suggest it may be a legacy therapeutic with limited modern clinical expansion.
LOE Approaching
LOE-stage product with moderate competitive pressure (30%) suggests a contracting brand team and declining commercial opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for PRISCOLINE roles, reflecting its LOE-approaching lifecycle stage. Career progression on this product will be limited; professionals should consider transfer opportunities within Novartis to higher-growth franchises.
Brand ManagerField Sales
Worked on PRISCOLINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.